In accordance with guidelines of health care reform of China and Shanghai, the social health care department will make full use of its advantages of centralized procurement management, give full play to the linkage mechanism of departments, continuously improve the formation mechanism of medical device price market, screen varieties with large usage, clear boundaries and full competition, and explore a new mode of strategic purchase of health care devices on the basis of transparent procurement.

China will speed up the marketing of new medicines by optimizing the approval procedures for clinical trials and accepting overseas clinical trial data and other reform tasks. The National Medical Products Administration has further accelerated the examination and approval of new medicines by implementing such measures as priority review, changing the application for clinical research from express license to implied license, and changing bioequivalence tests from review and approval to filing. Shanghai will cooperate to further improve the new medicine approval system and speed up the efficiency of new medicine review and approval.

All the medical institutions are qualified for vaccination as soon as they satisfy relevant conditions and standards.

Pneumonia vaccination for the elderly over 60 years old has been a major public health program in Shanghai since 2011. Foreign vaccine companies are welcomed to join in vaccine selection as immunization strategy is further adjusted.

Shanghai is now preparing the new medicine adjustment list, which will include rare diseases with great attention.

New round of policies are under preparation, and the value of medical services will be fully considered in medical service adjustment.

Recently, the Office of the National Organizations Drug Centralized Procurement and Use Pilot Working Group has drawn up a monitoring plan for the pilot project, requiring all pilot areas to closely monitor the implementation, discover problems and risks in time, and accumulate data for evaluation. As required by the office, Shanghai Municipal Medical Insurance Bureau is studying the detailed rules for implementation of the monitoring plan, and is comprehensively organizing data collection, review, summary, analysis and submission to make preparations for overall evaluation.

The competent government department will not designate certain brands for hospitals, and hospitals will make decisions in consideration of price, performance and after-sales services. There are also no restrictions on lease of medical devices.

There are over 50 commanding centers in Shanghai that evaluate information and data reported by chest pain, heart and heart and cerebral vessels, thus improving the medical quality.

The pilot of quantitative purchase in Shanghai has played an important role in eliminating medicine commissions, reducing the inflated price of medicines, and promoting the healthy development of the pharmaceutical industry. The bidding and purchase are stable and receive wide praise from all sectors of society. Next step, we will continue to give full play to the demonstration effect of quantitative purchase pilot in Shanghai as required for organizing the centralized purchase and use of medicines to ensure smooth initiation of pilot project in Shanghai.